Isatin-benzoazine molecular hybrids as potential antiproliferative agents: synthesis and in vitro pharmacological profiling

References

• BérubéGAn overview of molecular hybrids in drug discoveryExpert Opin Drug Discov2016113 281 30526727036
   PubMed Web of Science ®Google Scholar
• FortinSBérubéGAdvances in the development of hybrid anticancer drugsExpert Opin Drug Discov201388 1029 104723646979
   PubMed Web of Science ®Google Scholar
• Viegas-JuniorCDanuelloAda Silva BolzaniVBarreiroEJFragaCAMolecular hybridization: a useful tool in the design of new drug prototypesCurr Med Chem20071417 1829 185217627520
   PubMed Web of Science ®Google Scholar
• MeunierBHybrid molecules with a dual mode of action: dream or reality?Acc Chem Res2008411 69 7717665872
   PubMed Web of Science ®Google Scholar
• GloverVHalketJMWatkinsPJClowAGoodwinBLSandlerMIsatin: identity with the purified endogenous monoamine oxidase inhibitor tribulinJ Neurochem1988512 656 6593392550
   PubMed Web of Science ®Google Scholar
• VineKLMatesicLLockeJMRansonMSkropetaDCytotoxic and anticancer activities of isatin and its derivatives: a comprehensive review from 2000–2008Anticancer Agents Med Chem200994 397 41419442041
   PubMed Web of Science ®Google Scholar
• SunLLiangCShirazianSDiscovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinaseJ Med Chem2003467 1116 111912646019
   PubMed Web of Science ®Google Scholar
• PrenenHCoolsJMentensNEfficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylateClin Cancer Res2006128 2622 262716638875
   PubMed Web of Science ®Google Scholar
• MotzerRJMichaelsonMDRedmanBGActivity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinomaJ Clin Oncol2006241 16 2416330672
   PubMed Web of Science ®Google Scholar
• McCormackPLNintedanib: first global approvalDrugs2015751 129 13925430078
   PubMed Web of Science ®Google Scholar
• RothGJHeckelAColbatzkyFDesign, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)J Med Chem20095214 4466 448019522465
   PubMed Web of Science ®Google Scholar
• KrugMHilgerothARecent advances in the development of multi-kinase inhibitorsMini Rev Med Chem2008813 1312 132718991750
   PubMed Web of Science ®Google Scholar
• IbrahimHSAbou-SeriSMAbdel-AzizHA3-Hydrazinoindolin-2-one derivatives: chemical classification and investigation of their targets as anticancer agentsEur J Med Chem2016122 366 38127391135
   PubMed Web of Science ®Google Scholar
• Abdel-AzizHAElsamanTAl-DhfyanAAttiaMIAl-RashoodKAAl-ObaidARSynthesis and anticancer potential of certain novel 2-oxo-N′-(2-oxoindolin-3-ylidene)-2H-chromene-3-carbohydrazidesEur J Med Chem201370 358 36324177362
   PubMed Web of Science ®Google Scholar
• EldehnaWMAltoukhyAMahrousHAbdel-AzizHADesign, synthesis and QSAR study of certain isatin-pyridine hybrids as potential anti-proliferative agentsEur J Med Chem201590 684 69425499988
   PubMed Web of Science ®Google Scholar
• HassanTAKadiAAAbdel-AzizHANovel N, N′-hydrazino-bis-isatin derivatives with selective activity against multidrug-resistant cancer cellsUnited States Patent USUS201202528602012
   Google Scholar
• IbrahimHSAbou-seriSMIsmailNSElaasserMMAlyMHAbdel-AzizHABis-isatin hydrazones with novel linkers: synthesis and biological evaluation as cytotoxic agentsEur J Med Chem2016108 415 42226706352
   PubMed Web of Science ®Google Scholar
• GudipatiRAnreddyRNMandaSSynthesis, anticancer and antioxidant activities of some novel N-(benzo[d]oxazol-2-yl)-2-(7-or 5-substituted-2-oxoindolin-3-ylidene)-hydrazinecarboxamide derivativesJ Enzyme Inhib Med Chem2011266 813 81821476831
   PubMed Web of Science ®Google Scholar
• TaherATKhalilNAAhmedEMSynthesis of novel isatin-thiazoline and isatin-benzimidazole conjugates as anti-breast cancer agentsArch Pharm Res20113410 1615 162122076761
   PubMed Web of Science ®Google Scholar
• SolomonVRHuCLeeHHybrid pharmacophore design and synthesis of isatin–benzothiazole analogs for their anti-breast cancer activityBioorg Med Chem20091721 7585 759219804979
   PubMed Web of Science ®Google Scholar
• HavrylyukDKovachNZimenkovskyBVasylenkoOLesykRSynthesis and anticancer activity of isatin-based pyrazolines and thiazolidines conjugatesArch Pharm (Weinheim)20113448 514 52221681810
   PubMed Web of Science ®Google Scholar
• RamshidPKJagadeeshanSKrishnanAMathewMNairSAPillaiMRSynthesis and in vitro evaluation of some isatin-thiazolidinone hybrid analogues as anti-proliferative agentsMed Chem201065 306 31221073435
   PubMed Web of Science ®Google Scholar
• KaminskyyDKhylukDVasylenkoOZaprutkoLLeskyRA facile synthesis and anticancer activity evaluation of spiro [thiazolidinone-isatin] conjugatesSci Pharm2011794 763 77722145104
   PubMedGoogle Scholar
• HavrylyukDZimenkovskyBVasylenkoOGzellaALesykRSynthesis of new 4-thiazolidinone-, pyrazoline-, and isatin-based conjugates with promising antitumor activityJ Med Chem20125520 8630 864122992049
   PubMed Web of Science ®Google Scholar
• WangSZhaoYZhangGLvYZhangNGongPDesign, synthesis and biological evaluation of novel 4-thiazolidinones containing indolin-2-one moiety as potential antitumor agentEur J Med Chem2011468 3509 351821621880
   PubMed Web of Science ®Google Scholar
• SolomonVRHuCLeeHDesign and synthesis of anti-breast cancer agents from 4-piperazinylquinoline: a hybrid pharmacophore approachBioorg Med Chem2010184 1563 157220106668
   PubMed Web of Science ®Google Scholar
• SharmaMSharmaSBuddhirajaASaxenaAKNepaliKBediPMSSynthesis and cytotoxicity studies of 3, 5-diaryl N-acetyl pyrazolineisatin hybridsMed Chem Res20142310 4337 4344
   Web of Science ®Google Scholar
• CohenMHJohnsonJRChenYFSridharaRPazdurRFDA drug approval summary: erlotinib (Tarceva) tabletsOncologist2005107 461 46616079312
   PubMed Web of Science ®Google Scholar
• ThorntonKKimGMaherVEVandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: US Food and Drug Administration drug approval summaryClin Cancer Res20121814 3722 373022665903
   PubMed Web of Science ®Google Scholar
• BoldGAltmannKHFreiJNew anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesisJ Med Chem20004312 2310 232310882357
   PubMed Web of Science ®Google Scholar
• DumasJDixonJAVEGF receptor kinase inhibitors: phthalazines, anthranilamides and related structuresExpert Opin Ther Pat2005156 647 65820141503
   PubMed Web of Science ®Google Scholar
• DeeksEDOlaparib: first global approvalDrugs2015752 231 24025616434
   PubMed Web of Science ®Google Scholar
• PinheiroACMendonça NogueiraTCde SouzaMVQuinoxaline nucleus: a promising scaffold in anti-cancer drug discoveryAnticancer Agents Med Chem20161610 1339 135227349448
   PubMed Web of Science ®Google Scholar
• WuWYCaoSLMaoBBSynthesis and antiproliferative evaluation of hybrids of indolin-2-one and quinazoline-4-(3H)-one linked via imine bondLett Drug Des Discov2013101 61 66
   Web of Science ®Google Scholar
• FaresMEldehnaWMAbou-SeriSMAbdel-AzizHAAlyMHTolbaMFDesign, synthesis and in vitro antiproliferative activity of novel isatin-quinazoline hybridsArch Pharm (Weinheim)20153482 144 15425664631
   PubMed Web of Science ®Google Scholar
• EldehnaWMFaresMCerusoMAmido/ureido substituted benzenesulfonamides-isatin conjugates as low nanomolar/subnanomo-lar inhibitors of the tumor-associated carbonic anhydrase isoform XIIEur J Med Chem2016110 259 26626840366
   PubMed Web of Science ®Google Scholar
• HeJWangXZhaoXLiangYHeHFuLSynthesis and antitumor activity of novel quinazoline derivatives containing thiosemicarbazide moietyEur J Med Chem201254 925 93022749192
   PubMed Web of Science ®Google Scholar
• El-FekySBayoumyBECyclocondensation of 4-benzyl-1-hydrazinophthalazineJ Prakt Chem19903326 1041 1048
   Google Scholar
• MakinoKSakataGMorimotoKOchiaiYA facile synthesis of novel tricyclic compounds, tetrazoloquinoxalines and 1, 2, 4-triazoloquinox-alinesHeterocycles1985238 2025 2034
   Web of Science ®Google Scholar
• GillHJTingleMDParkBKN-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemo-toxicityBr J Clin Pharmacol1995406 531 5388703658
   PubMed Web of Science ®Google Scholar
• LowryOHRosebroughNJFarrALRandallRJProtein measurement with the Folin phenol reagentJ Biol Chem19511931 265 27514907713
   PubMed Web of Science ®Google Scholar
• BillingsRESex differences in rats in the metabolism of phenytoin to 5-(3, 4-dihydroxyphenyl)-5-phenylhydantoinJ Pharmacol Exp Ther19832253 630 6366864524
   PubMed Web of Science ®Google Scholar
• QuaroniAWandsJTrelstadRLIsselbacherKJEpithelioid cell cultures from rat small intestine. Characterization by morphologic and immunologic criteriaJ Cell Biol1979802 248 26588453
   PubMed Web of Science ®Google Scholar
• SouleHDMaloneyTMWolmanSRIsolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10Cancer Res19905018 6075 60861975513
   PubMed Web of Science ®Google Scholar
• TodaroGJGreenHQuantitative studies of the growth of mouse embryo cells in culture and their development into established linesJ Cell Biol196317 299 31313985244
   PubMed Web of Science ®Google Scholar
• KumarGNSurapaneniSRole of drug metabolism in drug discovery and developmentMed Res Rev2001215 397 41111579440
   PubMed Web of Science ®Google Scholar
• CaldwellGWCompound optimization in early- and late-phase drug discovery: acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screensCurr Opin Drug Discov Devel200031 30 41
   PubMedGoogle Scholar
• KennedyTManaging the drug discovery/development interfaceDrug Discov Today1997210 436 444
   Web of Science ®Google Scholar